According to DPI specialist Iconovo, the European Patent Office has indicated that it plans to approve the company’s patent application for the ICOpre inhaler platform. In 2024, the FDA indicated that the ICOpre device is suitable as a substitute for GSK’s Ellipta inhaler in generic DPIs. Iconovo says that patent applications for the ICOpre are pending in the US and China.
Iconovo CEO Anders Månsson commented, “This patent will further strengthen the attractiveness of the ICOpre inhaler and as such it will enhance our efforts to partner the product for late-stage development and commercialization.”
In addition, Iconovo announced that it has initiated a feasibility study of its ICOone Nasal device for delivery of an unnamed compound “on behalf of a large multinational company” as part of a deal worth SEK 1 million. Iconovo says that the client will evaluate the device in user testing and, if successful, further development activities could follow. Iconovo is itself developing an intranasal semaglutide dry powder formulation delivered via the ICOone Nasal device.
Månsson said, “This agreement highlights the growing interest in our nasal delivery technology among large global players,. ICOone Nasal offers a simple, cost effective, and user friendly way to deliver prescription drugs or other products via the nasal route, an area of increasing importance for both therapeutic and consumer applications.”
Read the Iconovo press release on the ICOpre patent
Read the Iconovo press release on the ICOone Nasal feasibility study
